| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | 545.16% | Oppenheimer | → $16 | Assumes | → Outperform |
| 03/02/2021 | 625.81% | Oppenheimer | → $18 | Initiates Coverage On | → Outperform |
Evaxion Biotech Questions & Answers
The latest price target for Evaxion Biotech (NASDAQ: EVAX) was reported by Oppenheimer on July 18, 2022. The analyst firm set a price target for $16.00 expecting EVAX to rise to within 12 months (a possible 545.16% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Evaxion Biotech (NASDAQ: EVAX) was provided by Oppenheimer, and Evaxion Biotech their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a with a price target of $0.00 to $16.00. The current price Evaxion Biotech (EVAX) is trading at is $2.48, which is within the analyst's predicted range.